

Background information

- **Description:** Session 2.4 will examine vaccination recommendations and strategic plans for older adults in three EU countries (Portugal, Poland and Denmark).
- To include the same information topics in the 3 talks, we ask you to fill in the following template (slide 2) of your country (examples given for Belgium and Finland) and discuss this template and the questions on slide 3 during our meeting. You can remove slides 4 and 5.

		COVID-19	Influenza	Td(ap)	Pneumo	RSV	Shingles	Others?
Country	Are these vaccines recommended specifically for all older adults in the National/Regional Vaccination Program (NVP)?	Yes	Yes	Yes	Yes, if chronic disease	Yes, if COLD	Yes, if immunosuppressed	
	At what age are these vaccines recommended in the NVP?	65y +	65y +	Lifelong	65y +	60y+	adults	
	What is the recommended frequency of vaccination for older adults as per the NVP?	Annually	Annually	10 yr	Single dose	Single dose	Single dose	
	Do the recommendations in the NVP differ from those provided by the National Immunization Technical Advisory Group (NITAG)?	NA	NA	NA	NA	NA	NA	NA
	Which specific vaccine(s) are recommended for older adults in the NVP?	Comirnaty JN.1.	Vaxigrip-Tetra	generic	Prevenar 20®	Arexvy®	Shingrix	
	Is vaccination publicly funded for older adults? If partially reimbursed, what is the out-of-pocket cost?	Fully	Fully	Fully	Fully	Fully	Fully	
	What is the full price of the vaccine without reimbursement?	€134	€34	€47	€134	€256	€216	
	Who is authorized to administer the vaccine?	MD's and nurses	MD's and nurses	MD's	MD's	MD's	MD's	
	What is the cost of a HCP's visit (for vaccination)? Free for those reimbursed fully	€23	€23	€23	€23	€23	€23	
	What is the vaccination coverage rate in the target group (older adults)?	75%	76%	?	?	?	?	
	Target coverage?	90+%	90+%	?	?	?	?	
	Are healthcare providers (HCPs) also recommended for vaccination in the NVP?	No	Yes	No	No	No	No	HBV
	Are vaccines for HCPs reimbursed? If partially, what is their out-of-pocket cost?		fully					Fully

To discuss

- Briefly discuss the **current landscape**
 - Recommended vaccines for older adult
 - Eligibility
 - Access points
 - Key challenges
- **Future perspectives**
 - Potential new vaccinations
 - Changes in target groups/age
 - Areas for improvement in implementation